Skip to main content

The Globe and Mail

DiagnoCure hires U.S. dealer for expansion

Quebec's own DiagnoCure Inc. , which markets a colorectal cancer screening test, announced Tuesday it hired San Francisco-based JMP Securities to gain some traction in its U.S. subsidiary, DiagnoCure Oncology Laboratories.

The firm is staying mum about what exactly it wants JMP to do, but the U.S. dealer specializes in health care.

DiagnoCure's stock has moved sideways since the start of 2009. After trying to gain ground in Canada, the firm now sees much more potential south of the border where insurance companies are more willing to experiment with new procedures. Tuesday's announcement came after Valerie Palmieri was recently hired in April to head the U.S. operations.

Story continues below advertisement

In 2008 DiagnoCure launched a new colorectal screening test, known as Previstage, that screens colon tumours and the lymph nodes. The company said currently around 25 per cent of people who have a tumour in this region are told that the cancer hasn't spread, even though it actually has, because current screening measures aren't advanced enough. To prevent this, DiagnoCure's test looks much deeper into the tissue.

Report an error
About the Author
Reporter and Streetwise columnist

Tim Kiladze is a business reporter with The Globe and Mail. Before crossing over to journalism, he worked in equity capital markets at National Bank Financial and in fixed-income sales and trading at RBC Dominion Securities. Tim graduated from Columbia University's Graduate School of Journalism and also earned a Bachelor in Commerce in finance from McGill University. More

Comments are closed

We have closed comments on this story for legal reasons. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.